secwatch / observer
8-K filed April 19, 2024, 7:59 PM ET ticker BPTH CIK 0001133818
other material confidence high sentiment neutral materiality 0.55

Bio-Path Holdings raises $1.2M in registered direct offering and warrants

BIO-PATH HOLDINGS, INC.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

BIO-PATH HOLDINGS, INC. entered into Purchase Agreement with certain institutional investors valued at approximately $1.2 million (effective 2024-04-18).

Action
entry
Agreement
equity purchase
Counterparty
certain institutional investors
Value
approximately $1.2 million
Effective
2024-04-18
Exact text from the filing
On April 18, 2024, Bio-Path Holdings, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors, pursuant to which the Company agreed to sell, in a registered direct offering (the “Registered Direct Offering”), an aggregate of 375,000 shares (the “Shares”) of its common stock, par value $0.001 per share (“Common Stock”), for a purchase price per Share of $3.225 and gross proceeds of approximately $1.2 million.
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

BIO-PATH HOLDINGS, INC. entered into Engagement Letter with H.C. Wainwright & Co., LLC (effective 2024-03-22).

Action
entry
Agreement
underwriting
Counterparty
H.C. Wainwright & Co., LLC
Effective
2024-03-22
Exact text from the filing
On March 22, 2024, the Company entered into an engagement letter (the “Engagement Letter”) with H.C. Wainwright & Co., LLC (the “Placement Agent”).
View on SEC.gov

419 material agreements filed in the last 30 days. Browse all material agreements →

BIO-PATH HOLDINGS, INC. filing history →

Source: SEC EDGAR
accession 0001104659-24-049197
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.